Evenity (Romosozumab) vs Tymlos (Abaloparatide): Which Bone-Building Drug Is Right for You?

What These Two Drugs Actually Do to Bone

Both romosozumab and abaloparatide build bone rather than simply slowing its breakdown. That distinguishes them from bisphosphonates like alendronate or the RANKL inhibitor denosumab.

Romosozumab (Evenity) works by blocking sclerostin, a protein produced by osteocytes that normally puts a brake on bone formation. Blocking sclerostin simultaneously increases bone formation and modestly decreases bone resorption, a so-called dual effect that no other approved agent shares. A 12-month course is the entire approved treatment window. After 12 months, the drug is stopped and a bisphosphonate or denosumab must follow to preserve gains.

Abaloparatide (Tymlos) is a synthetic analog of parathyroid hormone-related protein (PTHrP). It preferentially binds the PTH1 receptor in a conformation that favors bone formation over bone resorption, a slight mechanistic advantage over teriparatide (Forteo). The approved course runs up to 24 months. Like romosozumab, it requires follow-on antiresorptive therapy once discontinued.

Why anabolic therapy at all?

Women who have already fractured, who have a T-score at or below negative 2.5 at the hip, or who have failed or cannot tolerate antiresorptives are candidates for anabolic-first therapy. The 2022 American Association of Clinical Endocrinology (AACE) guidelines now recommend anabolic-first treatment for women at very high fracture risk, defining that as a T-score at or below negative 3.0, a recent fracture within 12 months, or fracture on antiresorptive therapy.

The evidence foundation

The ARCH trial (NEJM, 2017) compared romosozumab followed by alendronate against alendronate alone in 4,093 postmenopausal women with osteoporosis and a prior vertebral fracture. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fracture risk by 48% compared with alendronate alone. The ACTIVE trial (JAMA, 2016) compared abaloparatide with teriparatide and placebo in 2,463 postmenopausal women. Over 18 months, abaloparatide reduced new vertebral fracture risk by 86% relative to placebo. These numbers are not directly comparable because the trials enrolled different populations, used different comparators, and ran for different durations.

Head-to-Head Comparison by Special Population

No randomized trial has compared romosozumab directly against abaloparatide. The comparisons below are network meta-analyses and clinical reasoning from population-level subgroup data.

Postmenopausal women with very high fracture risk

This is the population both drugs were approved for. ARCH enrolled women who already had a vertebral fracture, which is a stronger starting condition than the typical ACTIVE participant. Romosozumab produced a spine BMD gain of 13.3% at 12 months in ARCH, while abaloparatide produced a gain of 9.2% at 12 months in ACTIVE. Both figures exceed what teriparatide achieved in the same trials. For a woman who has fractured and needs the fastest possible structural repair, romosozumab's speed of BMD accrual is an advantage. But the ARCH population also had a higher rate of serious cardiac events in the romosozumab arm, a finding that shaped the drug's boxed warning.

Women with prior or current cardiovascular disease

This is where the comparison diverges most sharply. The ARCH trial found that serious cardiovascular events (combined MI, stroke, and cardiovascular death) occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group over 24 months. That imbalance led the FDA to add a boxed cardiovascular warning to Evenity. Evenity should not be used in women who have had an MI or stroke in the preceding year, and should be used with caution in women with established cardiovascular disease.

Abaloparatide carries no cardiovascular boxed warning. In ACTIVE, the rates of cardiovascular adverse events were similar across abaloparatide, teriparatide, and placebo groups. For a postmenopausal woman with a history of coronary artery disease, prior stroke, or significant atherosclerotic burden, abaloparatide is the safer anabolic choice. Her cardiologist should still be in the loop, but the risk calculus clearly favors Tymlos in this group.

Women with chronic kidney disease (CKD)

Clinicians frequently face the question of anabolic therapy in women with CKD stages 3 through 5, a population with both high fracture risk and complex mineral metabolism. No large dedicated trial of either agent has been run specifically in CKD stages 4 or 5. That evidence gap is real, and women with advanced CKD deserve to know it.

For romosozumab, the ARCH trial excluded women with an estimated GFR below 30 mL/min/1.73 m². A pharmacokinetic substudy found that mild-to-moderate CKD (eGFR 30 to 59) did not substantially alter romosozumab exposure, and no dose adjustment is specified in that range. However, hypocalcemia becomes a meaningful risk at lower eGFR because sclerostin inhibition increases bone mineral uptake rapidly; calcium and vitamin D adequacy must be confirmed before starting.

For abaloparatide, the prescribing information notes increased exposure in severe renal impairment, but no specific dose adjustment is mandated. The PTHrP mechanism raises concern about hypercalciuria in women with residual tubular function, and urinary calcium should be monitored in CKD stages 3 and higher. Both drugs require careful baseline and follow-up labs in any woman with renal compromise. A practical framework for this population:

• Confirm 25-OH vitamin D is above 30 ng/mL before starting either agent
• Check serum calcium at baseline, 4 weeks, and 12 weeks after initiation
• Avoid romosozumab if eGFR is below 30 or if the woman had a cardiac event in the past year
• Consider abaloparatide in CKD stage 3 with close monitoring; avoid in dialysis-dependent patients until more data exist

Women with glucocorticoid-induced osteoporosis

Glucocorticoid use is common in women with autoimmune conditions including rheumatoid arthritis, lupus, and inflammatory bowel disease, all of which are more prevalent in women than men. Glucocorticoid-induced osteoporosis (GIOP) affects both trabecular and cortical bone through suppression of osteoblast function, a mechanism that makes anabolic therapy a logical fit.

A dedicated romosozumab GIOP trial has not been completed as of this publication. ARCH did not isolate glucocorticoid users. Abaloparatide's ACTIVE trial similarly did not report a GIOP subgroup. Teriparatide has the strongest evidence base for GIOP from the VERO trial (Lancet, 2017), which many clinicians use as a proxy. For women on chronic glucocorticoids who cannot use teriparatide, both romosozumab and abaloparatide are used off-label for this indication, with abaloparatide currently favored given its more favorable safety profile in the absence of direct GIOP data for romosozumab.

Women with diabetes

Type 2 diabetes is associated with higher fracture risk despite normal or elevated BMD, because diabetes impairs bone quality and increases fall risk. The ARCH subgroup analysis did not find differential efficacy of romosozumab in women with diabetes, though numbers were not large enough to be definitive. Sclerostin inhibition may modestly improve insulin sensitivity in animal models, but no human metabolic benefit has been demonstrated.

For abaloparatide, a post-hoc ACTIVE analysis found consistent fracture reduction across glycemic subgroups. Hypercalcemia may be a slightly heightened concern in women with diabetic nephropathy. Neither drug affects glucose directly, so neither should be avoided solely because of diabetes, but the underlying renal status in women with long-duration type 2 diabetes warrants the CKD monitoring framework described above.

Switching Between Evenity and Tymlos: What the Evidence Says

Should you switch from Evenity to Tymlos, or the other way? This is a clinically common question with limited direct data.

After completing 12 months of romosozumab

The standard sequence after Evenity is a bisphosphonate or denosumab, not another anabolic agent. Switching from Evenity directly to Tymlos is not an approved or evidence-supported sequence. The ARCH trial's efficacy arm moved to alendronate, and the 2022 AACE guidelines endorse follow-on antiresorptive therapy after anabolic completion. Sequential anabolic therapy (anabolic after anabolic) has theoretical appeal but no large randomized trial support in this specific order.

If Evenity must be stopped early

A woman may need to stop romosozumab before completing 12 months due to an incident MI, a new stroke, or an adverse reaction. In that scenario, there are two clinical paths: switch to an antiresorptive to protect gains already made, or, if fracture risk remains very high and cardiovascular risk permits, consider abaloparatide for up to 24 months before moving to an antiresorptive. The latter approach is theoretical; no trial has tested it. The decision belongs to a specialist in metabolic bone disease in consultation with the patient's cardiologist.

Starting Tymlos after completing Evenity

The FDA approved sequence of romosozumab followed by alendronate in ARCH did not include a window for abaloparatide. Using Tymlos after Evenity would mean sequential anabolic therapy. The DATA-Switch trial (NEJM, 2015), which studied switching between teriparatide and denosumab, showed complex BMD trajectories that caution against assumptions about additive anabolic effects. Until a trial directly addresses Evenity-to-Tymlos sequencing, guidelines do not support this approach except in exceptional cases under specialist supervision.

Starting Evenity after completing Tymlos

This sequence also lacks a dedicated trial. Mechanistically, it is plausible, as PTHrP analogs and sclerostin inhibitors work through different pathways. However, the cardiovascular risks of romosozumab do not diminish simply because another anabolic was used first. Any consideration of this approach requires a cardiology clearance and a bone-specialist visit.

Sex-Specific Physiology: Why These Drugs Were Built for Women's Bones

Postmenopausal estrogen loss accelerates bone resorption dramatically. In the first five years after the final menstrual period, women can lose three to five percent of total bone mass per year, a rate far exceeding male age-related bone loss. Both anabolic agents were designed specifically around this biology.

Hormonal status and drug response

Neither romosozumab nor abaloparatide has been studied in perimenopausal women with fluctuating estrogen levels. Both are approved for postmenopausal women only. In the reproductive years, PTH-related signaling differs meaningfully from the estrogen-depleted state, and extrapolating ARCH or ACTIVE efficacy data to perimenopausal women is not justified.

Sclerostin levels rise after menopause as estrogen falls, which is part of why romosozumab's mechanism is particularly well-matched to the postmenopausal skeleton. A 2019 analysis in the Journal of Bone and Mineral Research found that sclerostin concentrations were significantly higher in postmenopausal women than in premenopausal women of similar age, supporting the biological rationale for Evenity in this population.

Body composition and dosing

Both drugs are given as fixed doses without weight-based adjustment. Women with very low body weight (below 40 kg) may have proportionally higher drug exposure, particularly with abaloparatide, which shows increased AUC in low-body-weight individuals based on population pharmacokinetic modeling in the ACTIVE dataset. No separate dosing recommendation exists, but clinicians should be alert to hypercalcemia risk in small-framed postmenopausal women.

Pregnancy, Lactation, and Contraception

Both romosozumab and abaloparatide are contraindicated in pregnancy and are not approved for use in premenopausal women. These drugs have not been assigned a formal pregnancy category under the current FDA labeling system (which replaced A/B/C/D/X categories in 2015), but animal reproductive data show fetal harm for both agents.

Romosozumab (Evenity)

Animal studies showed teratogenicity at doses producing clinical exposure multiples. The FDA prescribing information for Evenity states that the drug should not be used in women who are pregnant or may become pregnant. No human pregnancy data exist. Lactation transfer has not been studied; because the clinical indication is postmenopausal women, no lactation guidance is provided in the label.

Abaloparatide (Tymlos)

The FDA prescribing information for Tymlos similarly advises against use in pregnancy based on animal toxicology data showing skeletal abnormalities in offspring at supratherapeutic doses. No human pregnancy exposure data exist. Lactation transfer is unknown. Because both drugs are approved only for postmenopausal women, contraception guidance is not addressed in the official labeling, but any premenopausal woman with premature ovarian insufficiency who might be considered off-label should use reliable contraception if either agent is contemplated.

If you are perimenopausal and still having cycles, even irregular ones, both of these drugs sit outside the approved indication. Menopausal hormone therapy combined with antiresorptive treatment remains the better-studied approach for women in the perimenopause window, per The Menopause Society 2023 position statement.

Who Is a Candidate for Evenity vs Tymlos: A Life-Stage and Condition Frame

Postmenopausal women (best candidates for both)

Both drugs were studied almost exclusively in postmenopausal women aged 55 to 85. If you are in this group with severe osteoporosis, the choice between them depends on the factors below:

Favor Evenity (romosozumab) if:

• You need maximum spine BMD recovery in the shortest time (12 months of Evenity outperformed 18 months of abaloparatide on lumbar spine BMD in network analyses, though direct comparison data are lacking)
• You have no cardiovascular disease history and your cardiologist has no concern
• You need a once-monthly injection schedule that fits your routine better than daily injections

Favor Tymlos (abaloparatide) if:

• You have had a prior MI, stroke, or carry significant atherosclerotic burden
• You have CKD stage 3 and cardiovascular co-morbidity that makes romosozumab's risk-benefit less favorable
• You want up to 24 months of anabolic therapy rather than the fixed 12-month Evenity window
• You have a history of hypercalciuria, as teriparatide raises urine calcium more than abaloparatide does based on the ACTIVE trial comparator arm data

Women with PCOS or premature ovarian insufficiency (POI)

Women with POI develop low estrogen states before natural menopause and accumulate fracture risk earlier. Neither romosozumab nor abaloparatide is approved for this population. The data simply do not exist. Hormone therapy with or without bisphosphonates remains the evidence-supported approach for bone protection in POI, per ACOG Practice Bulletin 182. PCOS does not, on its own, substantially worsen bone density; anovulatory women with low estrogen within PCOS may be an exception.

Women with glucocorticoid-dependent autoimmune conditions

As described in the CKD section, both agents are used off-label in GIOP. If cardiovascular risk is low, romosozumab is a reasonable consideration; if cardiovascular risk is present, abaloparatide is preferred. The ACR 2022 GIOP guideline conditionally recommends teriparatide over bisphosphonates for very high-risk GIOP, a recommendation that many clinicians extend to abaloparatide given mechanistic similarity and the ACTIVE trial's superior fracture reduction over teriparatide.

Practical Considerations: Injection, Cost, and Follow-On Therapy

Evenity is given as two 105 mg subcutaneous injections at a single visit, once monthly, administered by a healthcare provider or self-injected at home after training. The 12-month course is fixed; there is no approved extension.

Tymlos is a once-daily 80 mcg subcutaneous self-injection from a prefilled pen device. The 24-month maximum means women who respond well have a longer anabolic window before transitioning to antiresorptives.

Cost is a real consideration. Both drugs carry list prices exceeding $2,000 USD per month without insurance coverage. Both manufacturers have patient assistance programs. Check your plan's specialty pharmacy tier before assuming coverage.

After completing either drug, antiresorptive follow-on therapy is not optional. Bone gains accumulated during anabolic therapy revert substantially within 12 to 24 months without follow-on treatment. The ARCH trial data showed that women who transitioned to alendronate after romosozumab maintained and even extended fracture protection. After Tymlos, alendronate, zoledronic acid, or denosumab are the evidence-supported options.

What Women Are Not Being Told About These Trials

Women have historically been under-represented in cardiovascular trials, but the osteoporosis field is a rare reversal: ARCH and ACTIVE enrolled almost exclusively women. The evidence base here is genuinely female-centered.

However, both trials enrolled predominantly white women. ARCH enrolled 84% white participants; ACTIVE enrolled approximately 78% white participants. Women of Asian descent have higher baseline osteoporosis prevalence and may have different fracture risk thresholds. Black women have historically higher BMD but are not immune to osteoporosis and may be undertreated. Extrapolating ARCH and ACTIVE results to racially diverse women requires clinical judgment. The evidence gap for non-white women is real, and your clinician should factor in your personal fracture history and body composition rather than leaning solely on population-derived T-score thresholds.